Replies to post #48263 on DNAprint Genomics (DNAG)

[bag8ger]

frog,

If I may:

"What are the possible sets of circumstances that might lead a competitive multi-national pharmaceutical company to relinquish it's license for a 'slam dunk' multi-billion dollar drug?"

They learned it wasn't slam-dunk after all. In fact they could do nothing with it.

"Next step. Of those sets of circumstances, which ones would prevent one of it's multi-national competitors from snapping up the license immediately it became available?"

Easy: If they can't do anything with it, we sure can't.

"What circumstances can be conceived that prevented all of the potential players in the global pharmaceutical business from entering into a bidding war to obtain said 'slam dunk' muti-billion dollar drug?"

Beth Israel didn't want a bidding war. They negotiated with someone who they have faith in being able to complete the project.

Too, friendships, prior relationships count with some people.

Of course, most of the above assumes there ever was a prior licensee. It's obvious you think there was, and judging from your comments, you must have been privy to the entire matter.

[Virgil Hilts]

Frogman,

I have to disagree with your definition of "starting over." If we really want to start at that beginning, we need to start with what we actually know about the first licensee. I am willing to accept E's blog as accurate. This was just reposted by Paul. Thanks, Paul. So let's start with Pfizer losing the license because they sat on it without taking action.

If this is true then it is unlikely that it was returned to BIDMC because it was deemed worthless.

So why didn't one of Pfizer's competitors jump on it? Maybe they did, but ultimately it is BIDMC's decision who they grant the license to. They were burned once by Big Pharma, perhaps they thought it was in their best interest to avoid Big Pharma on the second time around. Perhaps they thought it would be best to go with a company that would make the Super EPO their top priority, rather than a company who has other multibillion dollar projects that are higher priority. Also, let's look at the proof in the pudding. DNAPrint is making progress with the product. If I'm BIDMC it looks like I made a good decision. I give Gabriel full credit for landing this deal. I do not buy the arguement that BIDMC foisted off a rejected product onto DNAPrint.

Virgil